Search

How Can We Help You?

Video

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Lung Cancer Trials

Select Clinical Trial

Protocol Number: EA5181

Protocol Title:  Randomized phase III Trial of MEDI4736 as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC

Eligibility: Men or women, ages 18 and older, newly diagnosed, unresectable, histologically and/or cytologically confirmed Stage III NSCLC

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: EA5191

Protocol Title: A randomized phase III trial of Cabozantinib and Cabozantinib plus Nivolumab versus standard chemotherapy in patients with previously treated non-squamous NSCLC.

Eligibility: Men or women, ages 18 or older, with pathologically confirmed stage IV non-squamous NSCLC after progression on standard of care chemo/immunotherapy

Contact Information: (910) 715-2200

__________________________________________________________________________________________

Protocol Number: BA3011-002

Protocol Title: A Phase2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.

Eligibility: Men or women, ages 18 or older, diagnosed with metastatic non-small cell lung cancer, stage IV disease.

Contact Information: (910) 715-2200

_________________________________________________________________________________________

Protocol Number: Merck MS201923_0050

Protocol Title:  A Phase II, open-label, single-arm study of Berzosertib (M6620) in combination with Topotecan in participants with relapsed platinum-resistant small-cell lung cancer. 

Eligibility: Men or women, ages 18 and older, diagnosed with limited or extensive stage small cell lung cancer with confirmed progression within 90 days from completion of first-line or chemoradiation platinum-based treatment (carboplatin or cisplatin).

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: FDI-213

Protocol Title:  A Prospective Collection of Peripheral Blood from Adults for CYFRA 21-1, SCC and NSE Assay Reference Range Determination. 

Eligibility: Men or women, ages 22 and older, healthy individuals, individuals currently diagnosed with certain benign diseases, individuals newly diagnosed with NSCLC and SCLC lung cancer prior to treatment, and individuals diagnosed with certain cancers at any stage and any treatment timepoint.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: ALCHEMIST

Protocol Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Eligibility: Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC). 

Contact Information: (910) 715-2200

____________________________________________________________________________________________

 

Protocol Number: LUNGMAP

Protocol Title: Master Protocol to evaluate biomarker-driven therapies and immunotherapies in previously-treated non-small cell lung cancer (Lung-MAP Screening Study)

Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, DISEASE MUST BE EITHER ADVANCED, stage IIIB or IV or recurrent.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Gilead 6220, GS-US-576-6220

Protocol Title:  An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Eligibility: Stage IV non-small cell lung cancer with no prior treatment, no actionable genetic mutations

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: SWOG 1914; NCT04214262

Protocol Title:  A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage Non-Small Cell Lung Cancer

Eligibility: Men and women age 18 and older, diagnosed with Early Stage Non-Small Cell Lung Cancer that are not candidates for surgical resection.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: SWOG 1929; NCT04334941

Protocol Title:  Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Eligibility: Men and women age 18 and older, diagnosed with Extensive Stage Small Cell lung cancer.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Abbvie M18-868

Protocol Title:  Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Eligibility: Men or women, ages 18 and older, with locally advanced or metastatic non-squamous cell NSCLC with c-Met overexpression, who have received no more than 1 line of prior chemotherapy in the locally advanced or metastatic setting.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Gilead 577-6153

Protocol Title:  Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD- 1 Immunotherapy

Eligibility: Men or women, ages 18 and older, with pathologically confirmed stage IV NSCLC after progression on standard of care chemo/immunotherapy

Contact Information: (910) 715-2200

 

Specialties
Clara McLean House
Make a Donation
News & Events